SpringWorks Therapeutics Inc

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SpringWorks reports robust Q1 revenue, poised for patient-centric growth

SpringWorks Therapeutics demonstrated strong financial performance and market acceptance for OGSIVEO in Q1 2024.
The company's focus on patient-centric care and pipeline advancement positions them well for future growth and innovation.
While facing challenges in market competition and regulatory landscape, SpringWorks has opportunities for expansion and diversification.

SpringWorks reports robust Q2 earnings, focuses on expanding treatments

SpringWorks Therapeutics delivered strong financial performance in Q2 2024, driven by $40.2 million in net product revenue for OGSIVEO.
The company's focus on expanding OGSIVEO reach, advancing mirdametinib, and developing its emerging portfolio underscores its commitment to innovation.
While facing challenges such as rising operating expenses, SpringWorks remains well-positioned with a healthy cash reserve to pursue growth opportunities.
Strategically navigating challenges and capitalizing on opportunities will be crucial for SpringWorks to sustain its momentum and drive future success.

SpringWorks Therapeutics reports robust Q3 performance and eyes growth opportunities

SpringWorks Therapeutics demonstrates strong financial performance, a solid balance sheet, and positive market reception for their products. While regulatory hurdles exist, opportunities for growth through new approvals and expanded patient populations present promising prospects for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 7, 2024 to report its second quarter financial results and discuss recent business updates.

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for treating NF1-PN also hold promise.

SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why

SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.

SpringWorks (SWTX) Completes NDA Submission for Mirdametinib

NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm

STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, for the treatment of pediatric and adult patients with neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN).

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference, taking place in Miami, Florida on Tuesday, June 11, 2024 at 2:00 p.m. ET.

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

– Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral presentation –

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference, taking place in Las Vegas, Nevada on Tuesday, May 14, 2024 at 3:40 p.m. PT / 6:40 p.m. ET.

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

Start Time: 08:30 January 1, 0000 9:06 AM ET SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q1 2024 Earnings Conference Call May 02, 2024, 08:30 AM ET Company Participants Saqib Islam - CEO Francis Perier - CFO Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - CMO Samantha Sandler - Senior Director of IR Conference Call Participants Anupam Rama - JPMorgan Yaron Werber - TD Cowen Corinne Johnson - Goldman Sachs Peter Lawson - Barclays Alec Stranahan - Bank of America Michael Schmidt - Guggenheim Operator Good morning. My name is Tawanda, and I will be your conference operator today.

SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.18 per share a year ago.

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates

– Achieved $21.0 million in OGSIVEO ® (nirogacestat) net product revenue in the first quarter –

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors also accepted for presentations at ASCO – STAMFORD, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that data from the Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June 4, 2024.

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. E.T. on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates.

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

Arrowhead Pharmaceuticals

CRISPR Therapeutics

Cytokinetics

Halozyme Therapeutics

Jazz Pharmaceuticals

Viking Therapeutics

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role functioning, and quality of life Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role functioning, and quality of life

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

– Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 –

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

STAMFORD, Conn., Feb. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will present at the following investor conferences:

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., Jan. 31, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, taking place in New York, New York on Thursday, February 8, 2024 at 2:00 p.m. ET.

SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.

SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why

STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 a.m. ET), and a live webcast will be available at ir.springworkstx.com. Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.

SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 a.m. PT.

SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the closing of its previously announced underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,422,413 shares of common stock in this offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $316.25 million.

SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AGNC Investment

Crocs

Domino's Pizza

Federated Hermes

Groupon

Gravity Co

Gray TV

Hims & Hers Health

JD.com

Kamada

Malibu Boats

Methanex

OneMain Hld

PayPal

Semrush Holdings

Tarsus Pharmaceuticals

Tecnoglass

Vanguard S&P 500 ETF

WD-40

Wabash National

In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their top investing ideas. We've compiled all of their firsts here for your review and to showcase the new perspectives being offered on the platform.

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being sold by SpringWorks. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $275.0 million. The offering is expected to close on or about December 7, 2023, subject to the satisfaction of customary closing conditions. In addition, SpringWorks has granted the underwriters a 30-day option to purchase up to an additional 1,422,413 shares of its common stock at the public offering price, less underwriting discounts and commissions.

News for SpringWorks Therapeutics Inc Stock (SWTX)